Elevación de SPINK2 en leucemia mieloide aguda

Gezer Sümbül; Emrence Zeliha; Elverdi Tuğrul; Ar Muhlis Cem; Salman Yaylaz Burcu; Paçal Ferda; Ünüvar Ayşegül; Sarıman Melda; Eşkazan Ahmet Emre; Karaman Serap; Salihoğlu Ayşe; Karakaş Zeynep; Abacı Neslihan; Sırma-Ekmekci Sema

doi:10.1515/almed-2023-0011

Advances in Laboratory Medicine (Feb 2023)

Elevación de SPINK2 en leucemia mieloide aguda

Gezer Sümbül,
Emrence Zeliha,
Elverdi Tuğrul,
Ar Muhlis Cem,
Salman Yaylaz Burcu,
Paçal Ferda,
Ünüvar Ayşegül,
Sarıman Melda,
Eşkazan Ahmet Emre,
Karaman Serap,
Salihoğlu Ayşe,
Karakaş Zeynep,
Abacı Neslihan,
Sırma-Ekmekci Sema

Affiliations

Gezer Sümbül: Department of Genetics, Aziz Sancar Institute of Experimental Medicine, Istanbul University, Istanbul, Türkiye
Emrence Zeliha: Department of Genetics, Aziz Sancar Institute of Experimental Medicine, Istanbul University, Istanbul, Türkiye
Elverdi Tuğrul: Department of Internal Medicine, Cerrahpasa Faculty of Medicine, Division of Hematology, Istanbul University-Cerrahpasa, Istanbul, Türkiye
Ar Muhlis Cem: Department of Internal Medicine, Cerrahpasa Faculty of Medicine, Division of Hematology, Istanbul University-Cerrahpasa, Istanbul, Türkiye
Salman Yaylaz Burcu: Department of Genetics, Aziz Sancar Institute of Experimental Medicine, Istanbul University, Istanbul, Türkiye
Paçal Ferda: Department of Genetics, Aziz Sancar Institute of Experimental Medicine, Istanbul University, Istanbul, Türkiye
Ünüvar Ayşegül: Istanbul Faculty of Medicine, Division of Pediatric Hematology and Oncology, Istanbul University, Istanbul, Türkiye
Sarıman Melda: Department of Genetics, Aziz Sancar Institute of Experimental Medicine, Istanbul University, Istanbul, Türkiye
Eşkazan Ahmet Emre: Department of Internal Medicine, Cerrahpasa Faculty of Medicine, Division of Hematology, Istanbul University-Cerrahpasa, Istanbul, Türkiye
Karaman Serap: Istanbul Faculty of Medicine, Division of Pediatric Hematology and Oncology, Istanbul University, Istanbul, Türkiye
Salihoğlu Ayşe: Department of Internal Medicine, Cerrahpasa Faculty of Medicine, Division of Hematology, Istanbul University-Cerrahpasa, Istanbul, Türkiye
Karakaş Zeynep: Istanbul Faculty of Medicine, Division of Pediatric Hematology and Oncology, Istanbul University, Istanbul, Türkiye
Abacı Neslihan: Department of Genetics, Aziz Sancar Institute of Experimental Medicine, Istanbul University, Istanbul, Türkiye
Sırma-Ekmekci Sema: Department of Genetics, Aziz Sancar Institute of Experimental Medicine, Istanbul University, Istanbul, Türkiye

DOI: https://doi.org/10.1515/almed-2023-0011
Journal volume & issue: Vol. 4, no. 1
pp. 98 – 104

Abstract

Read online

La leucemia mieloide aguda (AML, por sus siglas en inglés) es una enfermedad muy heterogénea. Aunque se puede clasificar a los pacientes en grupos de riesgo según sus mutaciones genéticas, el pronóstico dentro de cada categoría varía sustancialmente. Es perentorio identificar nuevos marcadores moleculares de la AML. Recientemente, se ha descrito la elevación del inhibidor de la serina peptidasa Kazal tipo 2 (SPINK2) en la AML, habiendo sido relacionada con peores resultados clínicos en metaanálisis, así como en un número limitado de pacientes con AML.

Published in Advances in Laboratory Medicine

ISSN: 2628-491X (Online)
Publisher: De Gruyter
Country of publisher: Germany
LCC subjects: Medicine: Medicine (General): Medical technology
Website: https://www.degruyter.com/journal/key/almed/html

About the journal

Abstract

Keywords